Randomized trial of the Carpentier–Edwards supra-annular prosthesis versus the Medtronic Mosaic aortic prosthesis: 10-year results†

Abstract

clinicaltrial.gov ID 1301 (NCT03346044).

Intermediate-term outcomes of aortic valve replacement using a bioprosthesis with a novel tissue

“…Because this reflects both stent frame and sewing ring design and implantation technique, this may be taken as a reflection of the excellent results obtained in current surgical practice across the 27 cardiac surgical sites with varying approach and suturing methods. Endocarditis rates were low and consistent with contemporary studies with other valve designs, 27 again suggesting that RESILIA tissue does not impart any increased susceptibility to endocarditis.…”

Hypo-attenuated leaflet thickening in surgically-implanted mitral bioprosthesis

“…In the aortic valve domain, it is hypothesized that HALT exist along the spectrum of SVD in that HALT represents the earliest phase of SVD, with a more severe form manifesting in reduced leaflet motion and hemodynamically overt valve thrombosis, eventually leading to premature SVD [6,10]. Extrapolating from the excellent long-term durability of surgically implanted aortic valves [13] and a differential in the risk of HALT between SAVR and TAVR valves, the sequence of events likely occurs more commonly in TAVR valves compared to SAVR valves [2,14]. In our series, all three patients with HALT in bMV had hemodynamically occult HALT with mean PG in a normal range with normal leaflet motions on echocardiogram.…”